University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Welsh, Liam
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruiting
2/3
140
Europe, RoW
LAM561, TMZ, RT
Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS
Primary Glioblastoma, Glioblastoma Multiforme
10/24
05/25
5G-RUBY, NCT06630260: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting
1/2
182
Europe
Avutometinib, VS-6766, Defactinib, Temozolomide, Temodal
Institute of Cancer Research, United Kingdom, Minderoo Foundation, Verastem, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK, University of Cambridge
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
09/29
09/30
NCT04359745: Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression

Recruiting
N/A
500
Europe
Guy's and St Thomas' NHS Foundation Trust, King's College London
Glioblastoma
05/24
05/25
METRE, NCT04626206: Multi -paramEtric Imaging to Assess Treatment REsponse After Stereotactic Radiosurgery of Brain Metastases

Not yet recruiting
N/A
12
NA
Royal Marsden NHS Foundation Trust, National Institute for Health Research, United Kingdom
Brain Metastases, Adult
08/21
08/21
Benghiat, Helen
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruiting
2/3
140
Europe, RoW
LAM561, TMZ, RT
Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS
Primary Glioblastoma, Glioblastoma Multiforme
10/24
05/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26

Download Options